Back

Antiarrhythmic drugs - What, why, when to whom

19 March 2019 (11:54 - 12:12)
Organised by:
Congress Presentation Part of: Critical appraisal of antiarrhythmic drug therapy - The science behind trial-and-error Arrhythmias EHRA Premium Access EHRA 2019

About the speaker

Photo
Professor Gheorghe Andrei Dan

University of Medicine and Pharmacy Carol Davila, Bucharest (Romania)

4 More presentations in this session

Presentation thumbnail
The trials-and-errors of antiarrhythmic drug therapy
Professor J. Camm (London, GB)
Slides Video
Presentation thumbnail
Genetic basis for tailored drug therapy for ventricular arrhythmias
Associate Professor C. Remme (Amsterdam, NL)
Presentation thumbnail
Rationale behind development of novel drugs for atrial arrhythmias
Professor J. Heijman (Graz, AT)
Slides Video
Presentation thumbnail
Panel discussion
Video

Access the full session

Session thumbnail
Critical appraisal of antiarrhythmic drug therapy - The science behind trial-and-error

The Event

Event poster

EHRA 2019

19 March 2019 11:54 CET
You may be interested in
thumbnail
Congress Presentation
Treating the unknown: the use of anti-arrhtyhmic drugs in idiopathic ventricular fibrillation
14 April 2026
thumbnail
Congress Session
Novel arrhythmia treatments
24 June 2023
thumbnail
Congress Presentation
The EHRA 'ABC' of AADs: why I still need them and what it is the updated classification?
30 March 2025
thumbnail
Congress Presentation
3 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources